TScan cuts 75% of workforce, pauses Phase 3 ALLOHA-2, refocuses on in vivo solid tumors

TScan Therapeutics, Inc.

Workforce reduction ~75%; ~$4.1M employee-related costs; $55.0M cumulative savings through 2027; cash runway into Q4 2027.
Pauses Phase 3 ALLOHA-2 enrollment of TSC-101; 7 patients on treatment arm; 13/13 Cohort C patients show complete donor chimerism.
CFO Jason Amello and CMO Chrystal Louis terminated; CEO Gavin MacBeath assumes principal financial/accounting officer duties.
Nasdaq minimum bid price deficiency notice Aug 27, 2026; must regain $1.00 compliance by Feb 23, 2027.
Two in vivo TCR-T candidates (PRAME, MAGE-A4) advance to IND-enabling; IND Q3 2027, Phase 1 Q4 2027.

item 2.05 item 3.01 item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jason A. Amello

Chief Financial Officer

TCRX · TScan Therapeutics, Inc.

Effective: 2026-09-02
Filed: September 2, 2026, 7:22 AM ET

In connection with the Strategic Reorganization, effective as of September 2, 2026 (the “Effective Date”), the employment of Jason A. Amello, the Company’s Chief Financial Officer, and Chrystal Louis, M.D., MPH, the Company’s Chief Medical Officer, was terminated.

Departed

Chrystal Louis

Chief Medical Officer

TCRX · TScan Therapeutics, Inc.

Effective: 2026-09-02
Filed: September 2, 2026, 7:22 AM ET

In connection with the Strategic Reorganization, effective as of September 2, 2026 (the “Effective Date”), the employment of Jason A. Amello, the Company’s Chief Financial Officer, and Chrystal Louis, M.D., MPH, the Company’s Chief Medical Officer, was terminated.

Appointed

Gavin MacBeath

Principal Financial Officer and Principal Accounting Officer

TCRX · TScan Therapeutics, Inc.

Effective: 2026-09-02
Filed: September 2, 2026, 7:22 AM ET

As of the Effective Date, Gavin MacBeath, Ph.D., the Company’s Chief Executive Officer, assumed the duties of the principal financial officer and principal accounting officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jason A. Amello was terminated as Chief Financial Officer at TScan Therapeutics, Inc..

Action: terminated
Role: Chief Financial Officer

Exact text from the filing

In connection with the Strategic Reorganization, effective as of September 2, 2026 (the “Effective Date”), the employment of Jason A. Amello, the Company’s Chief Financial Officer, and Chrystal Louis, M.D., MPH, the Company’s Chief Medical Officer, was terminated.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Chrystal Louis was terminated as Chief Medical Officer at TScan Therapeutics, Inc..

Action: terminated
Role: Chief Medical Officer

Exact text from the filing

In connection with the Strategic Reorganization, effective as of September 2, 2026 (the “Effective Date”), the employment of Jason A. Amello, the Company’s Chief Financial Officer, and Chrystal Louis, M.D., MPH, the Company’s Chief Medical Officer, was terminated.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Gavin MacBeath was appointed as Principal Financial Officer and Principal Accounting Officer at TScan Therapeutics, Inc..

Action: assumed
Role: Principal Financial Officer and Principal Accounting Officer

Exact text from the filing

As of the Effective Date, Gavin MacBeath, Ph.D., the Company’s Chief Executive Officer, assumed the duties of the principal financial officer and principal accounting officer of the Company.

View on SEC.gov

TScan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-379343

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.